Literature DB >> 35754583

Bilateral consecutive choroidal neovascularization in Best vitelliform macular dystrophy.

Sandra Hoyek1, Lisa Y Lin1, Lindsay Klofas Kozek1, Efren Gonzalez2, Farrah Rajabi3, Nimesh A Patel1,2.   

Abstract

Best vitelliform macular dystrophy (BVMD) is a slowly progressive macular disease caused by a pathogenic variant of the Bestrophin (BEST1) gene. Examination coupled with multimodal imaging and genetic testing are used to guide diagnosis and treatment. A 12-year-old girl was examined for decreased vision in the left eye and showed bilateral "egg-yolk"-like macular lesions with choroidal neovascularization (CNV) in the left eye. Six months later, she experienced decreased vision with appearance of CNV on optical coherence tomography angiography in the right eye. Injections of anti-vascular endothelial growth factor helped restore vision from 20/125 to 20/20 in the right eye with stabilization of her left eye (vision 20/40). Genetic testing revealed c.851A > G (p.Tyr284Cys), a heterozygous variant of the BEST1 gene. The same variant was found in her father, who was initially misdiagnosed with toxoplasmosis due to a peripheral retinal lesion in the left eye. This is the first report of bilateral consecutive CNV secondary to BVMD. Additionally, it highlights the likely pathogenic role of a novel variant of the BEST1 gene.
Copyright © 2022 Baylor University Medical Center.

Entities:  

Keywords:  BEST1 gene; Best vitelliform macular dystrophy; choroidal neovascularization

Year:  2022        PMID: 35754583      PMCID: PMC9196779          DOI: 10.1080/08998280.2022.2071075

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN: 0899-8280


  12 in total

1.  The role of estrogen and estrogen receptorbeta in choroidal neovascularization.

Authors:  Mai Tanemura; Noriko Miyamoto; Michiko Mandai; Hiroshi Kamizuru; Sotaro Ooto; Tsutomu Yasukawa; Masayo Takahashi; Yoshihito Honda
Journal:  Mol Vis       Date:  2004-12-06       Impact factor: 2.367

2.  HORMONAL SUPPLEMENTATION TRIGGERING CHOROIDAL NEOVASCULARIZATION IN HEALTHY YOUNG FEMALES.

Authors:  Rosa Dolz-Marco; Nuria Doménech; Teresa Diago; Javier Montero; Sara García-Canet; Enrique Cervera-Taulet; Roberto Gallego-Pinazo; J Fernando Arévalo
Journal:  Retin Cases Brief Rep       Date:  2019 Spring

3.  Best's macular dystrophy in Australia: phenotypic profile and identification of novel BEST1 mutations.

Authors:  A C Cohn; C Turnbull; J B Ruddle; R H Guymer; L S Kearns; S Staffieri; H T Daggett; A W Hewitt; D A Mackey
Journal:  Eye (Lond)       Date:  2010-11-26       Impact factor: 3.775

4.  Clinical findings in eyes with BEST1-related retinopathy complicated by choroidal neovascularization.

Authors:  Mai Miyagi; Jun Takeuchi; Yoshito Koyanagi; Kei Mizobuchi; Takaaki Hayashi; Yasuki Ito; Hiroko Terasaki; Koji M Nishiguchi; Shinji Ueno
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-10-18       Impact factor: 3.117

5.  Intravitreal bevacizumab for choroidal neovascular membrane associated with Best's vitelliform dystrophy.

Authors:  Ekta Rishi; Pukhraj Rishi; Sheshadri Mahajan
Journal:  Indian J Ophthalmol       Date:  2010 Mar-Apr       Impact factor: 1.848

Review 6.  The spectrum of ocular phenotypes caused by mutations in the BEST1 gene.

Authors:  Camiel J F Boon; B Jeroen Klevering; Bart P Leroy; Carel B Hoyng; Jan E E Keunen; Anneke I den Hollander
Journal:  Prog Retin Eye Res       Date:  2009-04-16       Impact factor: 21.198

7.  "Novel p.Tyr284Cys BEST1 genotype-phenotype correlations of Vitelliform Macular Dystrophy in a family with incomplete penetrance".

Authors:  Lucas Antonio Garza-Garza; Rafael Baltazar Reyes León-Cachón; Marcelino Aguirre-Garza; Manuel Garza-Leon
Journal:  Ophthalmic Genet       Date:  2020-03-24       Impact factor: 1.803

8.  Multimodal imaging in Multifocal Best disease.

Authors:  Dhaivat Shah; Kumar Saurabh; Rupak Roy
Journal:  Indian J Ophthalmol       Date:  2018-09       Impact factor: 1.848

9.  Functional and clinical data of Best vitelliform macular dystrophy patients with mutations in the BEST1 gene.

Authors:  Giuseppe Querques; Jennyfer Zerbib; Rossana Santacroce; Maurizio Margaglione; Nathalie Delphin; Jean-Michel Rozet; Josseline Kaplan; Domenico Martinelli; Nicola Delle Noci; Gisèle Soubrane; Eric H Souied
Journal:  Mol Vis       Date:  2009-12-31       Impact factor: 2.367

10.  Mutation-Dependent Pathomechanisms Determine the Phenotype in the Bestrophinopathies.

Authors:  Anna-Lena Nachtigal; Andrea Milenkovic; Caroline Brandl; Heidi L Schulz; Lisa M J Duerr; Gabriele E Lang; Charlotte Reiff; Philipp Herrmann; Ulrich Kellner; Bernhard H F Weber
Journal:  Int J Mol Sci       Date:  2020-02-26       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.